Nov 6, 4:02 PM ET
Repligen closed private exchange and subscription transactions on November 6, 2026, issuing $1.0 billion of 0.25% Convertible Senior Notes due 2031. About $541.4 million of the new notes swapped out $456.8 million of its 1.00% notes due 2028, and $458.6 million was sold for cash. The filing shows the company took on new debt with a lower coupon and a conversion price about 20% above the October 29, 2026 closing price, which could mean future share dilution if holders convert.
- Issued $1.0 billion of 0.25% Convertible Senior Notes due November 1, 2031, with interest paid semi-annually starting May 1, 2027
- Exchanged $456.8 million of 1.00% 2028 notes for $541.4 million of new notes; $143.2 million of 2028 notes remain outstanding
- Initial conversion price of about $226.37 per share, roughly 20% above the $188.64 closing price on October 29, 2026
- Up to 5,301,100 shares of common stock may be issued on conversion, including make-whole additional shares
Read the filing on SEC.gov ↗
Oct 30, 6:04 AM ET
Repligen plans to issue $1.0 billion of 0.25% convertible senior notes due 2031, with about $541.4 million issued in exchange for $456.8 million of its 1.00% notes due 2028 and about $458.6 million sold for cash. The company says it will use about $120.0 million of the cash proceeds to repurchase common stock at $188.64 per share, and closing is expected on or about November 6, 2026. For shareholders, the deal refinances part of the 2028 notes and could lead to up to 5,301,100 new shares on conversion, while the related share repurchases could affect the stock price.
- Exchange: about $456.8 million of 2028 notes swapped for about $541.4 million of new notes; the company receives no cash from this part.
- Cash sale: about $458.6 million of new notes sold for cash, with about $120.0 million used to repurchase shares at $188.64.
- Initial conversion price is about $226.37, a 20.0% premium to the October 29, 2026 last sale price; up to 5,301,100 shares could be issued on conversion.
- Closing is expected on or about November 6, 2026; about $143.2 million of 2028 notes will remain outstanding.
Read the filing on SEC.gov ↗
Oct 27, 7:04 AM ET
Repligen reported third-quarter 2026 revenue of $209.3 million, up 11% from $188.8 million a year earlier, and raised its full-year 2026 revenue guidance to $844 million-$852 million. The company swung to a GAAP loss of $0.68 per diluted share, driven by a $41.2 million intangible asset impairment charge, though adjusted EPS rose to $0.53 from $0.46.
- Q3 revenue $209.3 million vs. $188.8 million a year earlier, up 11% as reported and 12.5% organic
- GAAP loss per diluted share $0.68 vs. EPS of $0.26, including a $41.2 million intangible asset impairment charge
- Adjusted diluted EPS $0.53 vs. $0.46; FY26 revenue guidance raised to $844 million-$852 million
- BioLife Solutions acquisition closed October 6, 2026; cash and marketable securities $863 million at September 30, 2026
Read the filing on SEC.gov ↗
Oct 6, 9:14 AM ET
Repligen said on October 6, 2026 that it completed its acquisition of BioLife Solutions, under a merger agreement dated July 21, 2026. BioLife shareholders received $11.25 in cash and 0.1442 Repligen common shares for each BioLife share, and BioLife's stock is set to stop trading and be removed from Nasdaq. Repligen has not yet quantified the deal's expected effect on its 2026 outlook and plans to address it on its third quarter 2026 earnings call.
- Each BioLife share converted into 0.1442 Repligen common shares plus $11.25 in cash, per the filing.
- The Mergers closed on October 6, 2026; BioLife notified Nasdaq of the closing that day.
- BioLife common stock was to be halted after the after-market session on October 5, 2026, and suspended as of the close on October 6, 2026.
- Repligen will provide details on the transaction's expected impact on its 2026 outlook on its third quarter 2026 earnings call.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.